HCPLive

Pap Testing Moving Toward Alignment with Guidelines

 
FRIDAY, Jan. 4 (HealthDay News) -- Increasing numbers of women are receiving Papanicolau (Pap) screening for cervical cancer at an age and with a frequency consistent with the latest guidelines, according to two studies published in the Jan. 4 issue of the U.S. Centers for Disease Control and Prevention's Morbidity & Mortality Weekly Report.

Mona Saraiya, M.D., from the CDC in Atlanta, and colleagues assessed trends in Pap testing using data from the Behavioral Risk Factor Surveillance System (BRFSS; 2000 to 2010) for 125,297 18- to 30-year-old women. The researchers found that, among women aged 18 to 21 years, there was an increase in the percentage reporting never having been tested (26.3 to 47.5 percent) and a decrease in the percentage reporting having had a Pap test in the past 12 months (from 65.0 to 41.5 percent). For women aged 22 to 30 years, the proportion never tested increased from 6.6 to 9.0 percent, and the proportion who had a Pap test in the previous year decreased from 78.1 to 67.0 percent.

In a second study, Meg Watson, M.P.H., also from the CDC, and colleagues assessed recent screening behaviors and trends using data from the BRFSS for women aged 30 years and older. The researchers noted a decrease in the proportion of women reporting having had a hysterectomy who had undergone a recent Pap test (within three years), from 73.3 percent in 2000 to 58.7 percent in 2010. These decreases were consistent among women aged 30 to 64 years, for women aged 65 and older, and for women aged 65 years and older with no history of hysterectomy.

"Research is needed to determine how to further reduce unnecessary screening," write the authors of an editorial note accompanying the second study. "Monitoring Pap test prevalence among U.S. women is important to ensure that resources are targeted to women with the most need."
 

Full Text - Saraiya
Full Text - Watson


Copyright © 2013 HealthDay. All rights reserved.
 

Most Popular

Recommended Reading

Medications in general can take a long time to develop. Depending on the condition they treat that process can be even longer as more questions have to be answered before they can be introduced to the field. This is particularly true of multiple sclerosis treatments.
As a treatment for multiple sclerosis teriflunomide has shown benefits over a long development period and has proven effective in the treatment of patients with the relapsing-remitting form of the condition.
For as many drugs and therapies as there are for multiple sclerosis some are more aggressive than others. Alemtuzumab's approach is more on the aggressive end of the spectrum.
During a time when antibiotic resistance concerns are at an all-time high, a Texas-based team called for backup in the fight against pneumonia.
$vacMongoViewPlus$ $vAR$